Document:

Document

Exhibit 10.2 
NON-QUALIFIED STOCK OPTION AWARD AGREEMENT
RED ROCK RESORTS, INC.
2016 Equity Incentive Plan
This NON-QUALIFIED STOCK OPTION AWARD AGREEMENT (this “Agreement”), is made as of [          ] (the “Grant Date”) between Red Rock Resorts, Inc., a Delaware corporation (the “Company”), and [          ] (the “Participant”), and is made pursuant to the terms of the Company’s 2016 Equity Incentive Plan (the “Plan”).  Capitalized terms used herein but not defined shall have the meanings set forth in the Plan. 
Section 1.Option.  The Company hereby grants to the Participant, as of the Date of Grant, the right and option (this “Option”) to purchase [          ] Shares, at a price per Share equal to $[          ] (the “Exercise Price”), subject to such vesting, transfer and other restrictions and conditions as set forth in this Agreement (the “Award”).  This Option is not intended to qualify as an Incentive Stock Option.
Section 2.Vesting Requirements.
(a)Generally. Except as otherwise provided herein, 33 1/3% of this Option shall vest and become exercisable on the second, third, and fourth anniversaries of [          ] (each, a “Vesting Date”), subject to the Participant’s continuous service or employment with the Company and its Affiliates (“Service”) from the Grant Date through the applicable Vesting Date.
(b)Termination of Service.  Subject to Section  12 of the Plan, upon the occurrence of a termination of the Participant’s Service for any reason (other than the death or Disability of the Participant), the unvested portion of this Option shall immediately be forfeited and cancelled, and the Participant shall not be entitled to any compensation or other amount with respect thereto. Subject to Section 12 of the Plan, upon the occurrence of a termination of the Participant’s Service due to the death or Disability of the Participant, the unvested portion of this Option, together with the unvested portion of any other options previously granted to the Participant under the Plan that are outstanding as of the date of such death or Disability, shall immediately vest.  
Section 3.Term.  This Option shall terminate upon the earliest to occur of the following:
(a)Expiration. This Option shall terminate immediately upon the seventh anniversary of the Grant Date (the “Expiration Date”).
(b)Death; Disability.  If the Participant’s Service is terminated due to the Participant’s death or Disability, then the vested portion of this Option (including any portion of this Option or any option previously granted to Participant under the Plan that, in either case, vested under Section 2(b) above as a result of the Participant’s death or Disability) shall remain exercisable until the Expiration Date (at which time this Option shall be cancelled).
(c)Involuntary Termination.  In the event of an Involuntary Termination of the Participant’s Service, the vested portion of this Option shall remain exercisable  until the later of 90 days following such termination and the end of the first open trading period following such termination (at which time this Option shall be cancelled), but in no event later than the Expiration Date.
(d)Cause.  If the Participant’s Service is terminated for Cause, then this Option (both the vested and unvested portions) shall be cancelled immediately upon the occurrence of such termination.
(e)Other Terminations of Service.  If the Participant’s Service is terminated in a manner that is not otherwise specified in this Section 3, then the vested portion of this Option shall remain exercisable until the later of 30 days following such termination and the end of the first open trading period following such termination (at which time this Option shall be cancelled), but in no event later than the Expiration Date.

Section 4.Exercise.  Subject to the terms of this Agreement and the Plan, the vested portion of this Option may be exercised, in whole or in part, in cash or in any other form of legal consideration that may be acceptable to the Committee in accordance with the terms of the Plan.
Section 5.Restrictions on Transfer.  No portion of this Option (nor any interest therein) may be sold, assigned, alienated, pledged, attached or otherwise transferred or encumbered by the Participant otherwise than by will or by the laws of descent and distribution, and any such purported sale, assignment, alienation, pledge, attachment, transfer or encumbrance shall be void and unenforceable against the Company or any Affiliate; provided that the designation of a beneficiary shall not constitute a sale, assignment, alienation, pledge, attachment, transfer or encumbrance.  Notwithstanding the foregoing, at the discretion of the Committee, this Option may be transferred by the Participant solely to the Participant’s spouse, siblings, parents, children and grandchildren or trusts for the benefit of such persons or partnerships, corporations, limited liability companies or other entities owned solely by such persons, including, but not limited to, trusts for such persons.
Section 6.Investment Representation.  Upon acquisition of Shares pursuant to this Option at a time when there is not in effect a registration statement under the Securities Act of 1933, as amended (the “Securities Act”) relating to the Shares, the Participant hereby represents and warrants, and by virtue of such acquisition shall be deemed to represent and warrant, to the Company that the Shares shall be acquired for investment and not with a view to the distribution thereof, and not with any present intention of distributing the same, and the Participant shall provide the Company with such further representations and warranties as the Company may require in order to ensure compliance with applicable federal and state securities, blue sky and other laws.  No Shares shall be acquired unless and until the Company and/or the Participant shall have complied with all applicable federal or state registration, listing and/or qualification requirements and all other requirements of law or of any regulatory agencies having jurisdiction, unless the Committee has received evidence satisfactory to it that the Participant may acquire such shares pursuant to an exemption from registration under the applicable securities laws.  Any determination in this connection by the Committee shall be final, binding and conclusive.  The Company reserves the right to legend any certificate or book entry representation of the Shares, conditioning sales of such shares upon compliance with applicable federal and state securities laws and regulations.
Section 7.Securities Laws/Legend on Certificates.  The issuance and delivery of certificates representing Shares acquired pursuant to this Option shall comply with all applicable requirements of law, including without limitation the Securities Act, the rules and regulations promulgated thereunder, state securities laws and regulations, and the regulations of any stock exchange or other securities market on which the Company’s securities may then be traded.  If the Company deems it necessary to ensure that the issuance of securities under the Plan is not required to be registered under any applicable securities laws, each Participant to whom such security would be issued shall deliver to the Company an agreement or certificate containing such representations, warranties and covenants as the Company which satisfies such requirements. The certificates representing the Shares acquired pursuant to this Option shall be subject to such stop transfer orders and other restrictions as the Committee may deem reasonably advisable, and the Committee may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.
Section 8.Adjustments.  The Award granted hereunder shall be subject to the adjustment as provided in Section 4(b) of the Plan.
Section 9.No Right of Continued Service.  Nothing in the Plan or this Agreement shall confer upon the Participant any right to continued Service.
Section 10.Tax Withholding.  This Agreement and the Award shall be subject to tax and/or other withholding in accordance with Section 16(e) of the Plan.
Section 11.No Rights as a Stockholder; No Dividends.  The Participant shall not have any privileges of a stockholder of the Company with respect to this Option, including without limitation any right to vote any Shares underlying this Option or to receive dividends or other distributions in respect thereof, unless and until Shares underlying this Option are delivered to the Participant following the exercise of this Option in accordance with Section 4 hereof.
2

Section 12.Clawback.  The Award will be subject to recoupment in accordance with any existing clawback policy or clawback policy that the Company adopts or is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law.  The implementation of any clawback policy will not be deemed a triggering event for purposes of any definition of “good reason” for resignation or “constructive termination.”
Section 13.Amendment and Termination.  Subject to the terms of the Plan, any amendment to this Agreement shall be in writing and signed by the parties hereto.  Notwithstanding the immediately-preceding sentence, subject to the terms of the Plan, the Committee may waive any conditions or rights under, amend any terms of, or alter, suspend, discontinue, cancel or terminate, this Agreement and/or the Award; provided that, subject to the terms of the Plan, any such waiver, amendment, alteration, suspension, discontinuance, cancellation or termination that would materially impair the rights of the Participant or any holder or beneficiary of the Award shall not be effective without the written consent of the Participant, holder or beneficiary.
Section 14.Construction.  The Award granted hereunder is granted by the Company pursuant to the Plan and is in all respects subject to the terms and conditions of the Plan.  The Participant hereby acknowledges that a copy of the Plan has been delivered to the Participant and accepts the Award hereunder subject to all terms and provisions of the Plan, which are incorporated herein by reference.  In the event of a conflict or ambiguity between any term or provision contained herein and a term or provision of the Plan, the Plan will govern and prevail.  The construction of and decisions under the Plan and this Agreement are vested in the Committee, whose determinations shall be final, conclusive and binding upon the Participant.
Section 15.Governing Law.  This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without giving effect to the choice of law principles thereof.
Section 16.Counterparts.  This Agreement may be executed in counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument.
Section 17.Binding Effect.  This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, executors, administrators, successors and assigns.
Section 18.Entire Agreement.  This Agreement and the Plan constitute the entire agreement between the parties with respect to the subject matter hereof and thereof, merging any and all prior agreements.
[SIGNATURES ON FOLLOWING PAGE]
3

IN WITNESS WHEREOF, the parties hereto have executed this Agreement effective as of the Grant Date.
RED ROCK RESORTS, INC.
By:          
Name:          
Title:          
    

Signature Page to Non-Qualified Stock Option Award Agreement

PARTICIPANT:
        
Participant’s Signature             Date
Name:        
Address:            
Signature Page to Non-Qualified Stock Option Award Agreementlogc-ex101_30.htm

Exhibit 10.1

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT LOGICBIO THERAPEUTICS, INC. TERATS AS PRIVATE OR CONFIDENTIAL

 

AMENDMENT NO. 6
TO
AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT

THIS AMENDMENT NO. 6 TO THE AMENDED AND RESTATED EXCLUSIVE (EQUITY) AGREEMENT (the “Amendment No. 6”) is made as of March 29th, 2021 (“Amendment No. 6 Effective Date”), by and between The Board of Trustees of the Leland Stanford Junior University, an institution of higher education having powers under the laws of the State of California (“Stanford”), and LogicBio Therapeutics, Inc., a Delaware corporation (“LogicBio”).  Capitalized terms not otherwise defined herein shall have the meanings ascribed to them in that certain Amended and Restated Exclusive (Equity) Agreement, dated as of January 31, 2018, by and between Stanford and LogicBio, as amended by that certain Amendment No. 1 dated as of May 3, 2018, amended again by that certain Amendment No. 2 dated June 3, 2019, amended again by that certain Amendment No. 3 dated January 29, 2020, amended again by that certain Amendment No. 4 dated April 29, 2020, and amended again by that certain Amendment No. 5 dated October 30, 2020, to Amended and Restated Exclusive (Equity) Agreement (the “Original Agreement,” and as amended by this Amendment No. 6, the “Agreement”).

RECITALS

WHEREAS, the Parties desire to amend the Therapeutic Field of Use and certain milestone payments set forth in the Original Agreement;

WHEREAS, pursuant to Section 19.4 of the Original Agreement, the Original Agreement may be amended in writing executed by authorized representatives of Stanford and LogicBio; and

WHEREAS, in accordance with Section 19.4 of the Original Agreement, Stanford and LogicBio desire to amend the Agreement in the manner provided herein.

AGREEMENT

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, Stanford and LogicBio hereby agree as follows:

	
1.
	
Amendment of Agreement.

	
 
	
a.
	
Section 2.31 of the Original Agreement is hereby amended and restated in its entirety as follows:

 

 

“Therapeutics Field of Use” means human therapeutics to treat (a) methylmalonic acidemia (MMA), (b) propionic acidemia, (c) HIV, (d) influenza, (e) malaria, (f) Crigler Najjar Syndrome, (g) Tyrosinemia Type I, (h) Wilson’s disease, (i) hemophilia B, (j) Glycogen Storage Disease 1, (k) Glycogen Storage Disease 3, (l) progressive familial intrahepatic cholestasis type 2 (PFIC-2) with the ABCB11 gene, and (m) lysosomal acid lipase deficiency (LAL-D), including Wolman Disease, with the LIPA gene.

	
 
	
b.
	
Section 7.7(C) of the Original Agreement is hereby amended and restated in its entirety as follows:

Due one time for each subsequent Licensed Product in the Therapeutic Field of Use, Tissue Field of Use or [***] Field of Use or for Licensed Capsid Products that achieve the following milestones set forth in this section 7.7(C):

	
 
	
(1)
	
$[***] for filing an IND with the FDA (or equivalent with another regulatory body);

	
 
	
(2)
	
$[***] for dosing the first patient in a Phase II trial with the FDA (or equivalent with another regulatory body);

	
 
	
(3)
	
$[***] for dosing the first patient in a Phase III trial with the FDA (or equivalent with another regulatory body);

	
 
	
(4)
	
$[***] upon approval in the United States; and

	
 
	
(5)
	
$[***] upon commercial launch of the Licensed Product.

[For clarity, the last paragraph of Section 7.7 that begins “It is further agreed...” is not affected by this amendment.]

	
 
	
c.
	
Appendix C – Milestones of the Agreement, as amended by Amendment No. 5, is hereby amended by adding the two additional milestones below.

Additional Therapeutic Products

	
 
	
1.
	
[***]

	
 
	
2.
	
[***]

	
2.
	
Payment.  LogicBio will pay to Stanford a noncreditable, nonrefundable fee of [***] within [***] business days of its receipt of the invoice for such amount.

	
3.
	
Continued Validity of Agreement.  Except as specifically amended hereby, the Original Agreement shall continue in full force and effect as originally constituted and is ratified and affirmed by the parties hereto.

 

2

 

	
4.
	
Successors and Assigns.  The terms and conditions of this Amendment No. 6 shall inure to the benefit of and be binding upon the respective successors and assigns of the parties.  Nothing in this Amendment No. 6, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Amendment No. 6, except as expressly provided in this Amendment No. 6.

	
5.
	
Governing Law.  This Amendment No. 6 shall be governed by and construed in accordance with the laws of the State of California, United States of America, applicable to agreements negotiated, executed, and performed within California.

	
6.
	
Electronic Copy.  This parties to this Amendment No. 6 agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used.  The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature.

[Signature Page to follow]

 

 

 

3

 

 

The parties execute this Amendment in duplicate originals by their duly authorized officers or representatives.

THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

 

Signature: /s/ Sunita Rajdev

 

Name: Sunita Rajdev

 

Title: Senior Associate Director

 

 

LOGICBIO THERAPEUTICS, INC.

 

Signature: /s/ Kyle Chiang

 

Name: Kyle Chiang

 

Title: COO

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]